oral selective PI3K_ kinase inhibitor

<10 mg proj. human dose

from virtual screening and opt.

ACS Med. Chem. Lett., Nov. 19, 2020

Merck, Boston, CA

“compound 4d” (Merck oral selective PI3K delta kinase inhibitor)


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks